Articles

Dietary Intake by Patients Taking GLP-1 and Dual GIP/GLP-1 Receptor Agonists

Author(s): Sandra Christensen, MSN, ARNP, FNP-BC, MFOMA, FAANP
                   Katie Robinson, PhD, MPH, RD, LD, CNSC
                   Sara Thomas, PhD, RD
                   Dominique Williams, MD, MPH, FOMA, DIPL ABOM

Publication Date: 13 August 2024

 

Abstract:

Due to the high efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) for weight reduction and glycemic control, there is increased utilization for patients with obesity and/or T2DM. Yet, the impact of these medications on dietary intake is less understood. This narrative literature review summarizes clinical studies quantifying and characterizing dietary intake in people with obesity and/or T2DM using GLP-1 or GIP/GLP-1 RA.

Author Bio(s):

Sandra Christensen, MSN, ARNP, FNP-BC, MFOMA, FAANP

Obesity Specialist, Speaker & Author,
Integrative Medical Weight Management
Seattle, WA, USA

Katie Robinson, PhD, MPH, RD, LD, CNSC

Medical Science Liaison 
Scientific & Medical Affairs 
Abbott Nutrition 
Columbus, OH, USA

Sara Thomas, PHD, RD

Research Scientist Global Adult Nutrition Science
Abbott Nutrition Division of Abbott
Columbus, OH, USA

Dominique Williams, MD, MPH, FOMA, DIPL ABOM

Adult Nutrition Medical Director
Abbott
Columbus, OH, USA

Category